

September 20, 2013



Ceapro Announces Management Change

EDMONTON, ALBERTA -- (Marketwired) -- 09/20/13 -- **Ceapro Inc. (TSX VENTURE:CZO)** ("**Ceapro**" or "**the Company**") announces today that Mr. David Fielder, Ceapro's Chief Scientific Officer, is leaving the Company to pursue other interests. Effective immediately, Dr. Paul Moquin will manage Research and Development activities while other corporate functions previously under Mr. Fielder's responsibilities will be directly assumed by the President and CEO.

"Dr. Moquin's background and expertise is in line with the current transitioning of Ceapro towards other sectors like functional foods and nutraceuticals" said Gilles Gagnon, President and CEO of Ceapro. "We wish to thank Mr. Fielder for his long term contribution to Ceapro and we wish him all the best in his future endeavors" he added.

About Ceapro Inc.

Ceapro Inc. is a Canadian growth-stage biotechnology company. Primary business activities relate to the development and commercialization of active ingredients for personal care and cosmetic industries using proprietary technology and natural, renewable resources. To learn more about Ceapro, visit www.ceapro.com.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Ceapro Inc.
Gilles Gagnon
President & CEO
Telephone (Edmonton): 780.421.4555
ggagnon@ceapro.com
www.ceapro.com

Source: Ceapro Inc.